Company: SWKH
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001628280-25-040420
Chunk: 48

Company: SWK Holdings Corp
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 48
---
155 Pharmaceutical manufacturing, research and development expense— 645 — 645 Depreciation and amortization expense— — 19 19 General and administrative expense72 592 2,179 2,843 Other expense, net(67)— — (67)Income tax expense— — 1,026 1,026 Net income (loss)7,653 18 (4,135)3,536 Three Months Ended June 30, 2024Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$9,986 $804 $— $10,790 Other revenue57 — — 57 Provision for credit losses4,095 — — 4,095 Loss on impairment of intangible assets— 5,771 — 5,771 Interest expense225 2 892 1,119 Pharmaceutical manufacturing, research and development expense— 520 — 520 Change in fair value of acquisition-related contingent consideration— (4,900)— (4,900)Depreciation and amortization expense— 400 21 421 General and administrative expense91 747 2,082 2,920 Other income (expense), net3,851 — (37)3,814 Income tax expense— — 1,035 1,035 Net income (loss)9,483 (1,736)(4,067)3,680 

24

Six Months Ended June 30, 2025Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$19,255 $2,153 $— $21,408 Other revenue360 116 — 476 Benefit from credit losses(704)— — (704)Interest expense472 6 1,807 2,285 Pharmaceutical manufacturing, research and development— 1,403 — 1,403 Depreciation and amortization expense— — 38 38 General and administrative expense127 1,296 4,697 6,120 Other expense, net(2,281)(82)— (2,363)Income tax expense— — 2,304 2,304 Net income (loss)17,439 (518)(